Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.2000780
Abstract: AIMS High dose trivalent influenza vaccine (HD TIV) and adjuvant TIV (aTIV) have been developed specifically for adults aged 65 and older (65+) who are at high risk of life-threatening complications. However, there is a… read more here.
Keywords: ativ; influenza; cost; tiv ... See more keywords